- Paper Report
- Open Access
Truncated BRCA2 is cytoplasmic
- David Bertwistle
© Current Science Ltd 2000
- Published: 1 December 2000
- BRCA2 6174delT mutant
- green fluorescent protein
- nuclear localisation signal
Germ-line mutations in the breast cancer susceptibility gene BRCA2 predispose carriers to breast cancer. The vast majority of these mutations are predicted to lead to the production of a truncated BRCA2 protein, lacking the C terminus. Thus the C terminus of BRCA2 may contain an important functional domain.
To determine the biochemical function of the C-terminal region of BRCA2.
Immunofluorescence of 293T cells, transiently transfected with expression vectors for green fluorescent protein (GFP)-tagged BRCA2 fragments. Western blots of nuclear and cytoplasmic fractions of BRCA2 mutant cells.
Sequence analysis of BRCA2revealed the presence of four potential nuclear localisation signals (NLSs), three near the C terminus. Immunofluorescence of 293T cells, transfected with plasmids expressing GFP-tagged BRCA2 fragments, suggests that the C terminus of BRCA2 is responsible for nuclear translocation.
A series of plasmids encoding GFP-tagged, C-terminal fragments of BRCA2 containing mutations in the different putative NLSs were used for further immunofluorescence studies. These experiments indicate that only two of the possible NLSs, consisting of amino acids 3263-3269 and 3381-3385, are functional.
The pancreatic cancer cell line Capan-1 only has the 6174delT mutant form of BRCA2, which expresses a truncated BRCA2 protein, lacking both functional NLSs. Immunofluorescence of 293T cells transfected with a plasmid expressing GFP-tagged, 6174delT BRCA2 indicates that this truncated BRCA2 protein is located in the cytoplasm. Western blots of fractions of Capan-1 cells revealed that the endogenous 6174delT BRCA2 protein is also localised to the cytoplasm.
If the nuclear exclusion of truncated BRCA2 proteins is also observed in primary tumour samples, then individuals with truncating mutations in BRCA2could be screened by immunostaining.
Mice homozygous for some truncating mutations of Brca2suffer embryonic lethality. By contrast, some mice with other, more 3' truncating mutations survive to adulthood. These latter mice presumably produce a partially functional mutant Brca2 protein, yet this protein lacks the C terminus. It will therefore be interesting to see whether this mutant Brca2 protein localises to the nucleus.
RAD51, a nuclear protein, has been shown to interact with the 6174delT form of BRCA2, which lacks the NLSs and is localised to the cytoplasm. However, since this has been demonstrated by co-immunoprecipitation, the complex may form after lysis of the cells.